Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial (Q33401272)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial (English)

1 reference

Europe PubMed Central

26 July 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

object named as

Brian Schwartz

14

0 references

object named as

Edwin Choy

4

0 references

8

object named as

Ian Judson

1 reference

Europe PubMed Central

26 July 2017

George D Demetri

15

object named as

George D Demetri

1 reference

Europe PubMed Central

26 July 2017

author name string

Andrew J Wagner

1

1 reference

Europe PubMed Central

26 July 2017

John M Goldberg

2

1 reference

Europe PubMed Central

26 July 2017

Steven G Dubois

3

1 reference

Europe PubMed Central

26 July 2017

Lee Rosen

5

1 reference

Europe PubMed Central

26 July 2017

Alberto Pappo

6

1 reference

Europe PubMed Central

26 July 2017

James Geller

7

1 reference

Europe PubMed Central

26 July 2017

David Hogg

9

1 reference

Europe PubMed Central

26 July 2017

Neil Senzer

10

1 reference

Europe PubMed Central

26 July 2017

Ian J Davis

11

1 reference

Europe PubMed Central

26 July 2017

Feng Chai

12

1 reference

Europe PubMed Central

26 July 2017

Carol Waghorne

13

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

17 May 2012

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

118

1 reference

Europe PubMed Central

26 July 2017

23

1 reference

Europe PubMed Central

26 July 2017

5894-5902

1 reference

Europe PubMed Central

26 July 2017

MiT transcription factor associated malignancies in man.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Melanocytes and the microphthalmia transcription factor network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

The leucine zipper of TFE3 dictates helix-loop-helix dimerization specificity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

TFEB has DNA-binding and oligomerization properties of a unique helix-loop-helix/leucine-zipper family

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

c-Met expression is regulated by Mitf in the melanocyte lineage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Met, metastasis, motility and more

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Expression and mutational analysis of MET in human solid cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Chemotherapy in clear cell sarcoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Classification and subtype prediction of adult soft tissue sarcoma by functional genomics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Tumor response to sunitinib malate observed in clear-cell sarcoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Response to sunitinib malate in advanced alveolar soft part sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

21 January 2018

microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

7 January 2021

based on heuristic

inferred from DOI database lookup

Alveolar soft part sarcoma. a report of 15 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27582

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27582

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33401272&oldid=2111359260"